TCGA-P3-A5Q6-01A-11R-A28V-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.109589041
- sex
- male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-UY-A78M-01A-21R-A352-07 | — | — | 0.860 |
| 2 | TCGA-YC-A89H-01A-11R-A36F-07 | — | — | 0.829 |
| 3 | MNG581 | — | — | 0.825 |
| 4 | ERR2208967 | — | — | 0.824 |
| 5 | 15edd4fb-bb2d-4461-9c39-f4fac6b94ece | — | — | 0.817 |
| 6 | TCGA-05-4390-01A-02R-1755-07 | — | cohortA3 | 0.812 |
| 7 | aMVAC.P_013_TURBT_S232 | — | — | 0.811 |
| 8 | C3N-01024 | — | cohortA1 | 0.805 |
| 9 | TCGA-AC-A62V-01A-11R-A31O-07 | — | B | 0.787 |
| 10 | TCGA-UY-A9PD-01A-11R-A38B-07 | — | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |